No Detail Found!

Predictors and Outcomes of Slow Flow/No Reflow in Acute Myocardial Infarction Patients Treated with Pharmacoinvasive Strategies

Author(s)
Farman Ullah Department of Cardiology, Hayatabad Medical Complex,Peshawar,Pakistan
Muhammad Ilyas Khan Department of Cardiology, Hayatabad Medical Complex,Peshawar,Pakistan
Ejaz Ullah Department of Cardiology, Hayatabad Medical Complex,Peshawar,Pakistan
Inam Ullah Department of Cardiology, Hayatabad Medical Complex,Peshawar,Pakistan
Zubair Ahmad Department of Cardiology, Hayatabad Medical Complex,Peshawar,Pakistan
Waqas Fazal Department of Cardiology, Hayatabad Medical Complex,Peshawar,Pakistan
Abstract
Objectives: This study aimed to determine the incidence, predictors, and clinical outcomes of slow flow and no reflow (SF/NR) in patients undergoing a pharmacoinvasive strategy following full-dose thrombolytic therapy for acute myocardial infarction (AMI). Methodology: We conducted a prospective observational study at the Department of Cardiology, Hayatabad Medical Complex, Peshawar, from February 2022 to February 2023. The study cohort comprised 130 patients who received percutaneous coronary intervention (PCI) after thrombolytic therapy. Comprehensive data on patient demographics, clinical presentations, procedural details, and outcomes were systematically collected. Multivariate logistic regression was employed to identify independent predictors of SF/NR. Results: The incidence of SF/NR was 13.8%. Significant predictors included hypertension (Odds Ratio [OR]: 2.31, 95% Confidence Interval [CI]: 1.01-5.29, p = 0.047), high thrombus burden (OR: 3.14, 95% CI: 1.38-7.15, p = 0.006), and longer lesion length (OR: 1.29 per mm increase, 95% CI: 1.11-1.50, p < 0.001). Patients with SF/NR experienced significantly higher in-hospital mortality (16.7% vs. 2.7%, p = 0.012), cardiogenic shock (27.8% vs. 5.4%, p < 0.001), heart failure (33.3% vs. 7.1%, p < 0.001), and major adverse cardiac events (MACE) (44.4% vs. 11.6%, p < 0.001). At 30 days post-discharge, the mortality rate was 22.2% in the SF/NR group compared to 4.5% in the normal flow group (p = 0.004). Conclusion: The study highlights a significant incidence of SF/NR in patients undergoing PCI after thrombolytic therapy for AMI. Identified predictorshypertension, high thrombus burden, and longer lesion length-underscore the need for targeted risk stratification and management strategies to enhance patient outcomes and mitigate adverse effects.
Publication Details
Page(s) 188-193
Published Journal: Pakistan Heart Journal, Volume: 57, Issue: 3, Year: 2024

Request the full text from PASTIC

Keywords
No reflow, Thrombolytic therapy, Slow Flow, Acute myocardial infarction (AMI), Pharmacoinvasive strategy
References
Fan G,Wu X-G,Jiao W-P,Zhang H-K D-L .2022 .Safety and efficacy of intracoronary recombinant human prourokinase administration in patients with acute myocardial infarction and ST?segment elevation: A meta-analysis of randomized controlled trials. Exp Ther Med, 25 : 40.
Annibali G,Scrocca I,Aranzulla TC,Meliga E,Maiellaro F,Musumeci G .2022 ."No-Reflow" Phenomenon: A Contemporary Review. J Clin Med, 11 : 2233.
Khan MA,Samiullah JR,Shaikh JK,Butt MH,Hassan MU .2023 .Renal Dysfunction as a Predictor of Slow-Flow/No-Reflow Phenomenon and Impaired ST-Segment Resolution after Percutaneous Coronary Intervention in ST- Elevation Myocardial Infarction. A Retrospective Analysis. Pakistan J Med Heal Sci, 17 : 557-61.
Savic L,Mrdovic I,Asanin M,Lasica R,Krljanac G,Rajic D .2023 .The impact of kidney function on the slow-flow/no-reflow phenomenon in patients treated with primary percutaneous coronary intervention: registry analysis. Eur Hear J Acute Cardiovasc Care, 12 : .
Kumar R,Qayyum D,Ahmed I,Rai L,Mir A,Awan R,Cardiol J Interv .2023 .Predilation Ballooning in High Thrombus Laden STEMIs: An Independent Predictor of Slow Flow/No-Reflow in Patients Undergoing Emergent Percutaneous Coronary Revascularization. , : 1-6.
Søndergaard FT,Beske RP,Frydland M,Møller JE,Helgestad OKL,Jensen LO .2023 .Soluble ST2 in plasma is associated with postprocedural no-or-slow reflow after primary percutaneous coronary intervention in ST-elevation myocardial infarction. Eur Hear Journal Acute Cardiovasc Care, 12 : 48-52.
Singh R,Singla S,Singla A,Manchanda S,Kaur M. .2022 .Management of no reflow during percutaneous transcoronary angioplasty with catheter-directed intracoronary thrombolysis: A retrospective observational study. Int J Appl Basic Med Res, 12 : 260.
Xu B,Zhang C,Wei W,Zhan Y,Yang M,Wang Y .2023 .Effect of optimized thrombus aspiration on myocardial perfusion and prognosis in acute ST-segment elevation myocardial infarction patients with primary percutaneous coronary intervention. Front Cardiovasc Med, 10 : 1249924.
Gomez‐Lara J,Gracida M,Rivero F,Gutiérrez‐Barrios A,Muntané‐ Carol G,Romaguera R .2023 .Treatment of Slow‐Flow After Primary Percutaneous Coronary Intervention With FlowMediated Hyperemia: The Randomized RAIN‐FLOW Study. J Am Heart Assoc, 12(13) : e030285.
Grancini L,Diana D,Centola A,Monizzi G,Mastrangelo A,Olivares P .2023 .The SALINE Technique for the Treatment of the NoReflow Phenomenon during Percutaneous Coronary Intervention in STEMI. J Clin Med, 12 : 2405.
Gupta H,Parihar S,Tripathi VD .2022 .Assessment of the Efficacy and Safety of Early Intracoronary Nicorandil Administration in Patients With ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. , 14(5) : e25349.
Babapoor B,Sadeghieh-Ahari S,Sadeghi Hariri M,Shahbazzadegan B .2022 .Survey of effective factors in slow flow and no reflow in primary percutaneous coronary intervention patients. Int J Community Med Public Heal, 9 : 1222.
Godinez Cordova LB,Gonzalez-Pacheco H,Gopar-Nieto R,Eid-Lidt G,Briseno-De La Cruz JL,Araiza-Garaygordobil D .2022 .Prevalence and prognostic implications of the no-reflow phenomenon in patients undergoing primary percutaneous coronary intervention in a university center in a middle-income country. Eur Heart J, 43(Supplement) : ehac544-2066.
Darwish A,Frere A-F,Abdelsamie M,Awady W El .2022 .Intracoronary epinephrine versus adenosine in the management of refractory no-reflow phenomenon: a single-center retrospective cohort study. Ann Saudi Med, 42 : 75-82.
0

Citations

0

Downloads

98

Views